Loading clinical trials...

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites | Clinical Trials | Clareo Health

RECRUITINGPHASE1

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Single-arm Open Multicenter Study of IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion Tumors

NCT05268172•Affiliated Hospital of Jiangnan University

View on ClinicalTrials.gov

Summary

The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.

Detailed Description

Malignant pleural effusion is a common complication of malignant tumor, which usually indicates that the patient has reached the advanced stage, and about 30-40% of the patients are stubborn and refractory cases. The lack of standard therapeutic drugs and protocols in clinical practice seriously affects the anti-tumor treatment effect, quality of life and survival time of patients, and the prognosis is poor. IFN-γ can significantly induce the high expression of the costimulatory molecule ICAM-1 on tumor cells, thereby enhancing the killing of TUMOR cells by T cells. Moreover, IFN-γ can enhance the activity of CAR T cells in the presence of PD-L1-PD-1 pathway, and significantly improve the therapeutic effect of T cells on solid tumors. IFN-γ is an approved clinical treatment with known side effects and well-established symptomatic treatment. Although CIK is not a clinically approved drug, it has been used on a large scale in China with good safety and has entered the medical insurance of some provinces and cities. Tcm is an improved CIK cell and has good safety. Many clinical studies have been carried out, and no serious toxic and side effects have been observed.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female patients: ≥18 years old;
•2. Gastric cancer, colon cancer, lung cancer, lymphoma and other tumors confirmed by histology or cytology. The guidelines recommend entry to clinical trials in accordance with the standard treatment progression recommended by each disease guideline;
•3. According to iRECIST criteria, the patient should have at least one target lesion with measurable diameter line (tumor lesion CT scan length ≥10 mm, lymph node lesion CT scan short diameter ≥15 mm, scan thickness ≥ 5 mm); Or an unevaluable lesion, including but not limited to pleural effusion, bone metastasis, etc;
•4. ECOG physical condition score: 0-3;
•5. Estimated survival ≥3 months;
•6. Good function of major organs, that is, relevant examination indexes within the first 14 days of randomization meet the following requirements:(1)Routine blood test: 1)Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); 2)Neutrophil count \> 1.5×109/L; 3)Platelet count ≥ 90×109/L; (2)Biochemical examination: 1)Total bilirubin ≤ 1.5×ULN (upper limit of normal value); 2)Serum alanine aminotransferase (ALT) or AST ≤ 2.5×ULN; ALT or AST ≤ 5×ULN if liver metastasis was present; 3)Endogenous creatinine clearance ≥ 60 mL /min (Cockcroft-Gault formula); (3)Cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%;
•7. Signed informed consent;
•8. Good compliance, family members agreed to cooperate with survival follow-up.

Exclusion Criteria

•1. Participated in clinical trials of other drugs within four weeks;
•2. Patients have a history of other tumors, except cervical carcinoma in situ, treated squamous cell carcinoma or bladder epithelial tumor (Ta and TIS), or other malignant tumors that have received radical treatment (at least 5 years prior to enrollment);
•3. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as NYHA grade 2 or above heart failure, unstable angina pectoris, myocardial infarction within 1 year, and clinically significant ventricular or ventricular arrhythmias requiring treatment or intervention；
•4. For female subjects: surgically sterilized, postmenopausal, or have agreed to use a medically approved contraceptive during study treatment and for 6 months after the study treatment period; Serum or urine pregnancy tests must be negative during the 7 days prior to study enrollment and must be non-lactation. Male subjects: patients who are surgically sterilized or who have agreed to use a medically approved contraceptive during and for 6 months after the study treatment period；
•5. Patients with active tuberculosis, bacterial or fungal infection (grade ≥2 of NCI-CTC, 3rd edition); Have HIV infection, HBV infection, HCV infection；
•6. Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders;
•7. The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism); Subjects with vitiligo or asthma in complete remission during childhood without any intervention as adults could be included; Subjects with asthma requiring medical intervention with bronchodilators were excluded)；
•8. According to the judgment of the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's ability to complete the study.

Locations (1)

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

Key Dates

Start Date

December 20, 2022

Primary Completion Date

December 30, 2024

Completion Date

December 30, 2025

Last Updated

May 16, 2024

Enrollment

ESTIMATED participants

Conditions

Pleural Effusion, Malignant

Interventions

IFN-γ and CIK cells, Tcm cells or CAR T cells

DRUG

Contacts

liu quan, doctor

CONTACT

15995299079 Quanliu.lq@outlook.com

jiang li qing, postgraduate

CONTACT

15261479578 jjiangliq@163.com

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

NCT04684459

Peritoneal Carcinoma MetastaticPleural Effusion, Malignant+1 more

View study

NOT_YET_RECRUITINGPHASE1

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

NCT07443020

Malignant Pleural EffusionMalignant Mesothelioma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Inclusion Criteria

Exclusion Criteria

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Pleurodesis in Small-bore Chest Tube

Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

EDIT Management Feasibility Trial